Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results and Provide Corporate Update
To participate in the call, please dial (855) 779-9075 or (631) 485-4866 for international callers, and provide conference ID number 99339060. The webcast will be broadcast live on the investors section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About
Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics®, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon's Extreme Genetics® platform has yielded the first approved gene therapy product in the
The Xenon logo and "Extreme Genetics" are registered trademarks or trademarks of
Investor/Media Contact:Jodi Regts Senior Director, Corporate AffairsXenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: investors@xenon-pharma.com